Patents by Inventor David J. Dowling
David J. Dowling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240115693Abstract: Provided herein are nanoparticles which enhance the immunogenicity of antigens for use in Beta coronavirus (e.g., MERS-CoV, SARS-CoV-1, or SARS-CoV-2) vaccines, as well as immunogenic compositions comprising the antigen nanoparticles and additional adjuvants for further enhancing immunogenicity.Type: ApplicationFiled: June 23, 2022Publication date: April 11, 2024Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.Inventors: Francesco Borriello, Ofer Levy, David J. Dowling, Sirano Dhe-Paganon, Hyuk-Soo Seo
-
Publication number: 20230310438Abstract: Provided herein are TLR7/8 agonists to enhance immune responses or for use as adjuvants in fentanyl vaccines in opioid-using individuals.Type: ApplicationFiled: October 16, 2020Publication date: October 5, 2023Applicants: Children's Medical Center Corporation, the University of Montana, Regents of the University of MinnesotaInventors: David J. Dowling, Ofer Levy, Dheeraj Soni, Sharon Levy, Jay Evans, Marco Pravetoni, David Burkhart, Shannon Miller
-
Patent number: 11730810Abstract: Provided herein are imidazopyrimidine compounds, such as compounds of Formula (I), for use in enhancing human immune response and/or as adjuvants in vaccines.Type: GrantFiled: November 14, 2018Date of Patent: August 22, 2023Assignees: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.Inventors: Ofer Levy, David J. Dowling, Francesco Borriello, David A. Scott, Spencer E. Brightman, Frederic Feru
-
Publication number: 20230201340Abstract: Provided herein are adjuvantation systems for use in Beta coronavirus (e.g., MERS-CoV, SARS-CoV-1, or SARS-CoV-2) vaccines and immunogenic compositions comprising the adjuvantation system and a Beta coronavirus antigen.Type: ApplicationFiled: May 28, 2021Publication date: June 29, 2023Applicant: Children's Medical Center CorporationInventors: David J. Dowling, Ofer Levy, Francesco Borriello, Etsuro Nanishi, Timothy O'Meara, Yoshine Saito, Simon D. van Haren
-
Publication number: 20230201339Abstract: Provided herein are thiazole amide compounds (e.g., Formula (I)) for use in enhancing human immune response and/or as adjuvants in vaccines. The compounds described herein are used as enhancers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease). Also provided in the present disclosure are compositions (e.g., pharmaceutical composition), kits, methods, and uses including or using compounds described herein.Type: ApplicationFiled: September 16, 2020Publication date: June 29, 2023Applicant: Children's Medical Center CorporationInventors: David J. Dowling, Ofer Levy, Francesco Borriello
-
Patent number: 11673891Abstract: The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers and/or modifiers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease), or as stand alone anti-infective or immune response modifying agents. Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.Type: GrantFiled: November 14, 2018Date of Patent: June 13, 2023Assignees: Dana-Farber Cancer Institute, Inc., Children's Medical Center CorporationInventors: Ofer Levy, David J. Dowling, Francesco Borriello, David A. Scott, Spencer E. Brightman, Frederic Feru
-
Publication number: 20230132397Abstract: Provided herein are Toll-like receptor 2 (TLR2) agonists for use in enhancing human immune response and/or as adjuvants in vaccines. The TLR2 agonists include thiophenes, imidazoles, or phenyl-containing compounds, which may be compounds of Formulae (I), (II), (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.Type: ApplicationFiled: July 26, 2019Publication date: April 27, 2023Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.Inventors: David J. Dowling, Ofer Levy, Francesco Borriello, David A. Scott, Spencer E. Brightman
-
Patent number: 11633473Abstract: Provided herein are Stimulator of Interferon Genes (STING) ligand for use in enhancing immune response and/or as adjuvants in vaccines. In some embodiments, STING ligand is used alone or in combination with Alum in an adjuventation system for early life immunization.Type: GrantFiled: November 27, 2018Date of Patent: April 25, 2023Assignee: Children's Medical Center CorporationInventors: Ofer Levy, David J. Dowling, Francesco Borriello, Carlo Pietrasanta
-
Publication number: 20220242867Abstract: The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers and/or modifiers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease), or as stand alone anti-infective or immune response modifying agents. Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.Type: ApplicationFiled: November 14, 2018Publication date: August 4, 2022Applicants: Dana-Farber Cancer Institute, Inc., Children's Medical Center CorporationInventors: Ofer Levy, David J. Dowling, Francesco Borriello, David A. Scott, Spencer E. Brightman, Frederic Feru
-
Publication number: 20220118085Abstract: Provided herein are Toll-like receptor 2 (TLR2) agonists for use in enhancing human immune response and/or as adjuvants in vaccines. The TLR2 agonists include thiophenes, imidazoles, or phenyl-containing compounds, which may be compounds of Formulae (I), (II), (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.Type: ApplicationFiled: July 26, 2019Publication date: April 21, 2022Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.Inventors: David J. Dowling, Ofer Levy, Francesco Borriello, David A. Scott, Spencer E. Brightman
-
Publication number: 20210299250Abstract: Provided herein are Stimulator of Interferon Genes (STING) ligand for use in enhancing immune response and/or as adjuvants in vaccines. In some embodiments, STING ligand is used alone or in combination with Alum in an adjuventation system for early life immunization.Type: ApplicationFiled: November 27, 2018Publication date: September 30, 2021Applicant: Children's Medical Center CorporationInventors: Ofer Levy, David J. Dowling, Francesco Borriello, Carlo Pietrasanta
-
Publication number: 20210236632Abstract: Provided herein are Toll-like receptor 2 (TLR2) agonists for use in enhancing human immune response and/or as adjuvants in vaccines. The TLR2 agonists include thiophenes, imidazoles, or phenyl-containing compounds, which may be compounds of Formulae (I), (II), (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.Type: ApplicationFiled: July 26, 2019Publication date: August 5, 2021Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.Inventors: David J. Dowling, Ofer Levy, Francesco Borriello, David A. Scott, Spencer E. Brightman
-
Patent number: 10881729Abstract: Embodiments described herein relate to combinatorial compositions and uses thereof, for example, as vaccine adjuvant compositions, for enhancing immune response, for inducing differentiation of nave T cells to differentiate into IFN-?-producing T cells, and for preventing and treating infections. The combinatorial composition comprises TLR and CLR agonists. The combinatorial composition comprises at least one TLR4 agonist and at least one Dectin-1 agonist, wherein the at least TLR4 agonist is monophosphoryl lipid A (MPLA) or glycopyranosyl lipid A (GLA), or the combinatorial composition comprises at least one TLR7/8 agonist and at least one Mincle agonist.Type: GrantFiled: April 17, 2015Date of Patent: January 5, 2021Assignee: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Simon D. Van Haren, Ofer Levy, David J. Dowling
-
Publication number: 20200282048Abstract: Provided herein are imidazopyrimidine compounds for use in enhancing human immune response and/or as adjuvants in vaccines.Type: ApplicationFiled: November 14, 2018Publication date: September 10, 2020Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.Inventors: Ofer Levy, David J. Dowling, Francesco Borriello, David A. Scott, Spencer E. Brightman, Frederic Feru